viewProactive Group

Investor Update: Faron Pharma encouraged by Clevegen efficacy and tolerability

Top stories from the Proactive Investors UK newsroom.

Faron Pharmaceuticals (LON:FARN) has reported increased immune cell activity in its ongoing phase I/II trial of solid tumour cancer treatment Clevegen. All nine patients treated also tolerated high dose levels.

South African gold mine Pan African Resources (LON:PAF) has comfortably beaten its production forecast of 170,000 oz for the year to June. The miner has also forward sold 11% of production next year at a price of US$1,414 per oz.

Iofina (LON:IOF) increased iodine production by almost 10% in the first half of 2019.  Spot prices were also higher.

WPP shareholders are line for a £1bn special dividend after it sold a 60% stake in market research group Kantar to private equity group Bain.

Troubled holiday group Thomas Cook is talks about a £750mln injection of new money from major shareholder Fosun.

Insurer Hiscox has confirmed it will strengthen its reserves due to the rapidly escalating costs of Typhoon Jebi in Japan and Hurricane Michael in Florida. A  strong investment performance offset some of this additional cost and interim profits will be between US$150-170mln or little changed from last time.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Positive update on Cascadura for Touchstone Exploration

Touchstone Exploration (LON:TXP)says that the first stage of testing at the Cascadura-1ST1 well, at the Ortoire exploration project in Trinidad, has been suspended so the company can source alternative equipment capable of handling higher volumes of both natural gas and liquids. CEO Paul Baay...

13 hours, 26 minutes ago

2 min read